Business
Icon Group Deploys ChartCheck Adaptive Across Australia as Radformation Secures USFDA 510(k) Clearance
NEW YORK & MELBOURNE, Australia, February 18, 2026--Radformation, a leading provider of intelligent automation solutions for radiation oncology, and Icon Group (Icon), a leading global integrated cancer care provider, today announced the initial deployment of ChartCheck Adaptive, Radformation’s Offline Adaptive Assessment solution, across 15 cancer centres in Australia. The rollout reflects the growing clinical value of automated adaptive assessment workflows within routine radiotherapy practice
About this update from Icon Group Ltd
ChartCheck Adaptive brings quantitative insight into daily radiotherapy dose and anatomy changes. NEW YORK & MELBOURNE, Australia, February 18, 2026--(BUSINESS WIRE)--Radformation, a leading provider of intelligent automation solutions for radiation oncology, and Icon Group (Icon), a leading global integrated cancer care provider, today announced the initial deployment of ChartCheck Adaptive, Radformation’s Offline Adaptive Assessment solution, across 15 cancer centres in Australia. The rollout reflects the growing clinical value of automated adaptive assessment workflows within routine radiotherapy practice. Icon’s rollout of ChartCheck Adaptive has progressed steadily since November, with clinical teams reporting positive early experiences as the technology has been incorporated across multiple centres. The ability to gain consistent, automated insight into daily treatment delivery has supported clinical confidence and positive patient outcomes, while maintaining efficient workflows at scale. "We have been very pleased with the initial release and use of ChartCheck Adaptive across our Australian centres," said Trent Aland, Executive Manager, Clinical Care at Icon Group. "In head and neck cases alone, we are seeing positive early results for our patients, which has led to a number being re-planned due to anatomical changes during the course of their treatments. Having automated, quantitative insight into daily treatment progression supports confidence in clinical decision making without adding burden to our teams and, most importantly, delivering quality patient care." Icon Group has long partnered with Radformation to deploy high-quality, patient-centred automation solutions for radiotherapy across its global network. With ChartCheck Adaptive, Icon adds gold-standard dose recalculation and offline adaptive assessment, helping teams better understand how delivered dose evolves throughout a patient’s course of treatment. Following the success of the initial release, further releases are planned to commence from March, with the software expected to be fully deployed across all Icon Cancer Centre locations globally in the coming months. As an early adopter of ChartCheck Adaptive and a member of Radformation’s Centre of Excellence, Icon is actively working with Radformation to further enhance the software for wider and more mainstream...